Merck & Co. stock (US58933Y1055): Q1 earnings beat and Keytruda drives outperformance

Merck & Co. delivered first-quarter results that exceeded analyst expectations, with quarterly revenues up 11.6% to $9.1 million, driven by a 55.9% surge in the Richardson segment representing 58% of sales, according to Zacks as of recent report. The company's blockbuster drug Keytruda and new products continue to propel sales, while Animal Health contributes to overall growth. Shares have outperformed the Zacks Large Cap Pharmaceuticals industry (+45.6% vs. +19.9% over the past year).

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co.: core business model

Merck & Co., known outside the US as MSD, is a leading global healthcare company focused on discovering, developing, and providing innovative products and services in pharmaceuticals and vaccines. The company operates through two main segments: Pharmaceutical and Animal Health. Its portfolio includes therapies for cancer, infectious diseases, cardiovascular conditions, and more, with a strong emphasis on oncology.

Headquartered in Rahway, New Jersey, Merck & Co. invests heavily in R&D, spending billions annually to advance its pipeline. This model supports long-term growth through blockbuster drugs and a diversified Animal Health division serving livestock and companion animals worldwide.

Main revenue and product drivers for Merck & Co.

Keytruda, Merck's PD-1 inhibitor, remains the primary revenue driver, generating billions in sales for oncology treatments. Recent quarters show continued strength from this drug alongside new product launches, as highlighted in the Q1 beat reported by Zacks. Animal Health also bolsters results with vaccines and parasiticide products.

Valuation metrics indicate shares trade at 1.54X EV/sales and 8.68X EV/EBITDA, seen as discounts relative to industry peers, per recent analysis. These drivers position Merck for sustained performance amid US market demand for innovative therapies.

Industry trends and competitive position

The large cap pharmaceuticals sector faces patent cliffs but benefits from oncology and immunology advances. Merck & Co. holds a competitive edge with Keytruda's market leadership and a robust pipeline, outperforming the industry benchmark of +19.9% over the past year at +45.6%.

Why Merck & Co. matters for US investors

As a NYSE-listed giant (MRK) with major US headquarters and revenue exposure, Merck & Co. plays a key role in the US healthcare economy. Its drugs treat prevalent conditions, influencing S&P 500 health trends and offering retail investors exposure to global pharma growth.

Conclusion

Merck & Co. showcased resilient Q1 performance with beats on earnings and sales, powered by Keytruda and segment growth. Shares' outperformance and attractive valuations reflect strong fundamentals in a competitive pharma landscape. Investors track ongoing pipeline developments and market dynamics for future insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.